ABHD6
Abhydrolase domain containing 6 (ABHD6) is a serine hydrolyzing enzyme that possesses typical α/β-hydrolase family domains. ABHD6 was first studied because of its over-expression in certain forms of tumours.[1] In 2010, ABHD6 was linked to the endocannabinoid system as it controls the accumulation of 2-AG at the cannabinoid receptors.[2]. Alongside MAGL and ABHD12, ABHD6 controls 99% of 2-AG signalling in the brain.[3]
References
- ^ Li, F (2009 Apr). "An unannotated alpha/beta hydrolase superfamily member, ABHD6 differentially expressed among cancer cell lines". Molecular biology reports. 36 (4): 691–6. PMID 18360779.
{{cite journal}}: Check date values in:|date=(help); Unknown parameter|coauthors=ignored (|author=suggested) (help) - ^ Marrs, WR (2010 Aug). "The serine hydrolase ABHD6 controls the accumulation and efficacy of 2-arachidonoylglycerol (2-AG) at cannabinoid receptors". Nature neuroscience. 13 (8): 951–7. PMID 20657592.
{{cite journal}}: Check date values in:|date=(help); Unknown parameter|coauthors=ignored (|author=suggested) (help) - ^ Savinainen, J. R. (1 February 2012). "The serine hydrolases MAGL, ABHD6 and ABHD12 as guardians of 2-arachidonoylglycerol signalling through cannabinoid receptors". Acta Physiologica. 204 (2): 267–276. doi:10.1111/j.1748-1716.2011.02280.x.
{{cite journal}}: Unknown parameter|coauthors=ignored (|author=suggested) (help)